Patents by Inventor Eric J. Arts
Eric J. Arts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11920147Abstract: A synthetic lentiviral vector construct comprises a genomic RNA packaging enhancer (GRPE) element and lentiviral nucleic acid sequences sufficient for reverse transcription and packaging in a host cell.Type: GrantFiled: October 23, 2018Date of Patent: March 5, 2024Assignee: CASE WESTERN RESERVE UNIVERSITYInventor: Eric J. Arts
-
Publication number: 20230390377Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.Type: ApplicationFiled: March 7, 2023Publication date: December 7, 2023Inventors: Eric J. Arts, Jamie Mann
-
Patent number: 11596682Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.Type: GrantFiled: December 8, 2020Date of Patent: March 7, 2023Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Eric J. Arts, Jamie Mann
-
Patent number: 11192949Abstract: A method for inducing an immune response against HIV in a subject includes the step of preparing an HIV-1 gp120 envelope protein coding sequence particle having an N425K mutation, introducing the HIV-1 gp120 protein coding sequence particle having an N425K mutation into an expression construct using yeast homologous recombination, transfecting a cell with the expression construct, wherein the HIV-1 particle is secreted by the cell, and administering the secreted HIV-1 particle and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 particle stimulates an immune response in the subject.Type: GrantFiled: June 5, 2018Date of Patent: December 7, 2021Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Eric J. Arts, Annette Burkhouse
-
Patent number: 11105805Abstract: A method for determining HIV-1 co-receptor tropism in an HIV-infected patient includes preparing an HIV-1 envelope protein coding sequence from a sample, introducing the HIV-1 envelope protein coding sequence into a first expression construct using yeast homologous recombination, and using the first expression construct in a cell to cell fusion assay to determine HIV-1 co-receptor tropism.Type: GrantFiled: May 14, 2019Date of Patent: August 31, 2021Assignee: CASE WESTERN RESERVE UNIVERISTYInventors: Eric J. Arts, Alison Laing Wright, Kevin V. King, Miguel E. Quinones-Mateu
-
Publication number: 20210170015Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.Type: ApplicationFiled: December 8, 2020Publication date: June 10, 2021Inventors: Eric J. Arts, Jamie Mann
-
Patent number: 10857223Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.Type: GrantFiled: January 18, 2019Date of Patent: December 8, 2020Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Eric J. Arts, Jamie Mann
-
Publication number: 20200172987Abstract: A method for detecting low frequency occurrence of one or more HIV sequence variants associated with drug resistance and HIV tropism includes generating a plurality of cDNA species from a plurality of RNA molecules in an HIV sample population, amplifying a plurality of first amplicons and second amplicons from the cDNA species, wherein the first amplicons are amplified using first pairs of primers that amplify a HIV genomic region of the cDNA species encoding the Gag proteins p2, p7, p1 and p6, and the protease, reverse transcriptase, and integrase enzymes and the second amplicons are amplified using second pairs of primers that amplify a HIV genomic encoding region of the cDNA species encoding the env-C2V3 region; determining the nucleic acid sequence compositions of the amplified first amplicons second amplicons; identifying variants in the determined sequence by comparing the determined nucleic sequence to a guide sequence; and correlating the determined variants with variants of HIV drug resistance and HIType: ApplicationFiled: December 4, 2018Publication date: June 4, 2020Inventors: Miguel E. Quinones-Mateu, Eric J. Arts
-
Publication number: 20190339274Abstract: A method for determining HIV-1 co-receptor tropism in an HIV-infected patient includes preparing an HIV-1 envelope protein coding sequence from a sample, introducing the HIV-1 envelope protein coding sequence into a first expression construct using yeast homologous recombination, and using the first expression construct in a cell to cell fusion assay to determine HIV-1 co-receptor tropism.Type: ApplicationFiled: May 14, 2019Publication date: November 7, 2019Inventors: Eric J. Arts, Alison Laing Wright, Kevin V. King, Miguel E. Quinones-Mateu
-
Publication number: 20190211357Abstract: A synthetic lentiviral vector construct comprises a genomic RNA packaging enhancer (GRPE) element and lentiviral nucleic acid sequences sufficient for reverse transcription and packaging in a host cell.Type: ApplicationFiled: October 23, 2018Publication date: July 11, 2019Inventor: Eric J. Arts
-
Publication number: 20190151435Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.Type: ApplicationFiled: January 18, 2019Publication date: May 23, 2019Inventor: Eric J. Arts
-
Patent number: 10288613Abstract: A method for determining HIV-1 co-receptor tropism in an HIV-infected patient includes preparing an HIV-1 envelope protein coding sequence from a sample, introducing the HIV-1 envelope protein coding sequence into a first expression construct by providing a plasmid expression vector including a near-full length HIV-1 genome having a yeast uracil biosynthesis gene in place of a HIV-1 env coding sequencing and replacing the yeast uracil biosynthesis gene with the HIV-1 envelope protein coding sequence prepared from the patient sample, and using the first expression construct in a cell to cell fusion assay to determine HIV-1 co-receptor tropism.Type: GrantFiled: March 3, 2014Date of Patent: May 14, 2019Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Eric J. Arts, Alison Laing Wright, Kevin V. King, Miguel E. Quinones-Mateu
-
Publication number: 20190127466Abstract: A method for inducing an immune response against HIV in a subject includes the step of preparing an HIV-1 gp120 envelope protein coding sequence particle having an N425K mutation, introducing the HIV-1 gp120 protein coding sequence particle having an N425K mutation into an expression construct using yeast homologous recombination, transfecting a cell with the expression construct, wherein the HIV-1 particle is secreted by the cell, and administering the secreted HIV-1 particle and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 particle stimulates an immune response in the subject.Type: ApplicationFiled: June 5, 2018Publication date: May 2, 2019Inventors: Eric J. Arts, Annette Burkhouse
-
Patent number: 10272134Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes the steps of: preparing at least one HIV-1 protein coding sequence from a sample obtained from the subject, wherein the sample includes HIV-1 RNA; introducing the at least one HIV-1 protein coding sequence into at least one expression construct using yeast homologous recombination; transfecting a cell with the at least one expression construct, wherein the HIV-1 protein is secreted by the cell and administering a therapeutically effective amount of the secreted HIV-1 protein and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 protein stimulates latent HIV-specific memory-CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.Type: GrantFiled: May 8, 2017Date of Patent: April 30, 2019Assignee: CASE WESTERN RESERVE UNIVERSITYInventor: Eric J. Arts
-
Patent number: 10144976Abstract: A method for detecting low frequency occurrence of one or more HIV sequence variants associated with drug resistance and HIV tropism includes generating a plurality of cDNA species from a plurality of RNA molecules in an HIV sample population, amplifying a plurality of first amplicons and second amplicons from the cDNA species, wherein the first amplicons are amplified using first pairs of primers that amplify a HIV genomic region of the cDNA species encoding the Gag proteins p2, p7, p1 and p6, and the protease, reverse transcriptase, and integrase enzymes and the second amplicons are amplified using second pairs of primers that amplify a HIV genomic encoding region of the cDNA species encoding the env-C2V3 region; determining the nucleic acid sequence compositions of the amplified first amplicons second amplicons; identifying variants in the determined sequence by comparing the determined nucleic sequence to a guide sequence; and correlating the determined variants with variants of HIV drug resistance and HIType: GrantFiled: November 13, 2014Date of Patent: December 4, 2018Assignee: Case Western Reserve UniversityInventors: Miguel E. Quinones-Mateu, Eric J. Arts
-
Patent number: 10106816Abstract: A synthetic lentiviral vector construct comprises a genomic RNA packaging enhancer (GRPE) element and lentiviral nucleic acid sequences sufficient for reverse transcription and packaging in a host cell.Type: GrantFiled: December 16, 2013Date of Patent: October 23, 2018Assignee: Case Western Reserve UniversityInventor: Eric J. Arts
-
Patent number: 9988451Abstract: A method for inducing an immune response against HIV in a subject includes the step of preparing an HIV-1 gp120 envelope protein coding sequence particle having an N425K mutation, introducing the HIV-1 gp120 protein coding sequence particle having an N425K mutation into an expression construct using yeast homologous recombination, transfecting a cell with the expression construct, wherein the HIV-1 particle is secreted by the cell, and administering the secreted HIV-1 particle and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 particle stimulates an immune response in the subject.Type: GrantFiled: October 27, 2014Date of Patent: June 5, 2018Assignee: Case Western Reserve UniversityInventors: Eric J. Arts, Annette Burkhouse
-
Publication number: 20170239325Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes the steps of: preparing at least one HIV-1 protein coding sequence from a sample obtained from the subject, wherein the sample includes HIV-1 RNA; introducing the at least one HIV-1 protein coding sequence into at least one expression construct using yeast homologous recombination; transfecting a cell with the at least one expression construct, wherein the HIV-1 protein is secreted by the cell and administering a therapeutically effective amount of the secreted HIV-1 protein and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 protein stimulates latent HIV-specific memory-CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.Type: ApplicationFiled: May 8, 2017Publication date: August 24, 2017Inventor: Eric J. Arts
-
Patent number: 9642890Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes the steps of: preparing at least one HIV-1 protein coding sequence from a sample obtained from the subject, wherein the sample includes HIV-1 RNA; introducing the at least one HIV-1 protein coding sequence into at least one expression construct using yeast homologous recombination; transfecting a cell with the at least one expression construct, wherein the HIV-1 protein is secreted by the cell and administering a therapeutically effective amount of the secreted HIV-1 protein and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 protein stimulates latent HIV-specific memory-CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.Type: GrantFiled: June 10, 2015Date of Patent: May 9, 2017Assignee: Case Western Reserve UniversityInventor: Eric J. Arts
-
Patent number: 9487839Abstract: A method of detecting a single nucleotide polymorphism includes providing a first template polynucleotide, a second polynucleotide comprising a first and second sequence (complementary to a first portion of the first polynucleotide), and a third polynucleotide (complementary to a second portion of the first polynucleotide). The first, second and third polynucleotides are annealed, ligated and optionally, these steps are repeated. A fourth polynucleotide, which is essentially complementary to at least a portion of the first sequence, coupled to a first indicator is then provided. A fifth and/or sixth polynucleotide is provided. The fifth polynucleotide is essentially identical to at least a portion of the second sequence of the second polynucleotide and/or to at least a portion of the third polynucleotide. The sixth polynucleotide is essentially complementary to a portion of the second sequence of the second polynucleotide. The third or fifth polynucleotides may be coupled to a second indicator.Type: GrantFiled: September 29, 2009Date of Patent: November 8, 2016Assignee: Case Western Reserve UniversityInventors: Eric J. Arts, Matthew LaLonde